Un ringraziamento particolare a causa del National Health Laboratory Service (NHL), della Repubblica del Sud Africa per l&#39;organizzazione nazionale dei servizi connessi flusso di diagnostica HIV (http: \ \ www.nhls.ac.za e http://www.plgcd4 . netto). Gli studi presenti sono stati condotti presso il Dipartimento di Ematologia e Medicina Molecolare, Università di Witwatersrand (Johannesburg, Sud Africa, supportata da Capo Dipartimento, il professor Wendy Stevens). Gli autori non hanno ricevuto sovvenzioni per la pubblicazione da società commerciali o enti finanziatori. Le opinioni espresse sono quelle degli autori senza necessariamente riflettono il punto di vista delle Istituzioni dell&#39;Università di Witwatersrand o la NHL sudafricano.

<ol>
	<li>Mugyenyi, P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Routine+versus+clinically+driven+laboratory+monitoring+of+HIV+antiretroviral+therapy+in+Africa+(DART):+a+randomized+non-inferiority+trial.">Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomized non-inferiority trial.</a> Lancet. 375, 123-131 (2009).</li><li>Donnell, D., Kiarie, J., Thomas, K., Baeten, J., Lingappa, J., Cohen, C., Celum, C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=ART+and+risk+of+heterosexual+HIV-1+transmission+in+HIV-1+serodiscordant+African+couples:+A+Multinational+Prospective+Study.">ART and risk of heterosexual HIV-1 transmission in HIV-1 serodiscordant African couples: A Multinational Prospective Study.</a> , (2010).</li><li>Montaner, J., Wood, E., Kerr, T., Yip, B., Lima, V., Shannon, K., Harrigan, R., Hogg, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Association+of+Expanded+HAART+Coverage+with+a+Decrease+in+New+HIV+Diagnoses,+Particularly+among+Injection+Drug+Users+in+British+Columbia,+Canada.">Association of Expanded HAART Coverage with a Decrease in New HIV Diagnoses, Particularly among Injection Drug Users in British Columbia, Canada.</a> , (2010).</li><li>Petti, C. A., Polage, C. R., Quinn, T. C., Ronald, A. R., Sande, M. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Laboratory+medicine+in+Africa:+a+barrier+to+effective+health+care.">Laboratory medicine in Africa: a barrier to effective health care.</a> Clin Infect Dis. 42, 377-382 (2006).</li><li>Brown, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Global+health:+Great+expectations.">Global health: Great expectations.</a> BMJ. 334, 874-876 (2007).</li><li>Crisp, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Turning+the+World+Upside+Down.">Turning the World Upside Down.</a> Royal Society of Medicine Press. , (2009).</li><li>Hecht, R., Bollinger, L., Stover, J., McGreevey, W., Muhib, F., Madavo, C. E., de Ferranti, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Critical+choices+in+financing+the+response+to+the+global+HIV/AIDS+pandemic.">Critical choices in financing the response to the global HIV/AIDS pandemic.</a> Health Aff. 28, 1591-1605 (2009).</li><li>Lawrie, D., Coetzee, L. M., Glencross, D. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+model+for+continuous+quality+control+incorporating+sample-to+sample+assessment+of+optical+alignment,+fluorescence+sensitivity+and+volumetric+operation+fo+flow+cytometers.">A model for continuous quality control incorporating sample-to sample assessment of optical alignment, fluorescence sensitivity and volumetric operation fo flow cytometers.</a> Cytometry B Clin Cytom. 78, 201-208 (2010).</li><li>Loken, M. R., Brosnan, J. M., Bach, B. A., Ault, K. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Establishing+optimal+lymphocyte+gates+for+immunophenotyping+by+flow+cytometry.">Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry.</a> Cytometry. 11, 453-459 (1990).</li><li>Glencross, D., Scott, L. E., Jani, I. V., Barnett, D., Janossy, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=CD45-assisted+PanLeucogating+for+accurate,+cost-effective+dual-platform+CD4++T-cell+enumeration.">CD45-assisted PanLeucogating for accurate, cost-effective dual-platform CD4+ T-cell enumeration.</a> Cytometry. 50, 69-77 (2002).</li><li>Glencross, D. K., Janossy, G., Coetzee, L. M., Lawrie, D., Aggett, H. M., Scott, L. E., Sanne, I., McIntyre, J. A., Stevens, W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Large-scale+affordable+PanLeucogated+CD4++testing+with+proactive+internal+and+external+quality+assessment:+in+support+of+the+South+African+national+comprehensive+care,+treatment+and+management+programme+for+HIV+and+AIDS.">Large-scale affordable PanLeucogated CD4+ testing with proactive internal and external quality assessment: in support of the South African national comprehensive care, treatment and management programme for HIV and AIDS.</a> Cytometry B Clin Cytom. 74, S40-S51 (2008).</li><li>Dalgleish, A. G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+CD4+(T4)+antigen+is+an+essential+component+of+the+receptor+for+the+AIDS+retrovirus.">The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.</a> Nature. 312, 763-767 (1984).</li><li>Liu, Z., Cumberland, W. G., Hultin, L. E., Prince, H. E., Detels, R., Giorgi, J. V. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Elevated+CD38+antigen+expression+on+CD8++T+cells+is+a+stronger+marker+for+the+risk+of+chronic+HIV+disease+progression+to+AIDS+and+death+in+the+Multicenter+AIDS+Cohort+Study+than+CD4++cell+count.">Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count.</a> J Acquir Immune Defic Syndr Hum Retrovirol. 16, 83-92 (1997).</li><li>Glencross, D. K., Janossy, G., Coetzee, L. M., Lawrie, D., Scott, L. E., Sanne, I., McIntyre, J. A., Stevens, W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=CD8/CD38+activation+yields+important+clinical+information+of+effective+antiretroviral+therapy:+findings+from+the+first+year+of+the+CIPRA-SA+cohort.">CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: findings from the first year of the CIPRA-SA cohort.</a> Cytometry B Clin Cytom. 74, S131-S140 (2008).</li><li>Coetzee, L. M., Tay, S. S., Lawrie, D., Janossy, G., Glencross, D. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=From+research+tool+to+routine+test:+CD38+monitoring+in+HIV+patients.">From research tool to routine test: CD38 monitoring in HIV patients.</a> Cytometry B Clin Cytom. 76, 375-384 (2009).</li><li>Larsen, C. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+fragile+environments+of+inexpensive+CD4++T-cell+enumeration+in+the+least+developed+countries:+strategies+for+accessible+support.">The fragile environments of inexpensive CD4+ T-cell enumeration in the least developed countries: strategies for accessible support.</a> Cytometry B Clin Cytom. 74, S107-S116 (2008).</li><li>Glencross, D. K., Coetzee, L. M., Lawrie, D., Sanne, I., McIntyre, J. A., Janossy, G., Stevens, W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Longitudinal+monitoring+of+CD38+activation+can+obviate+costly+viral+load+testing+in+60%+of+patients+on+ART.">Longitudinal monitoring of CD38 activation can obviate costly viral load testing in 60% of patients on ART.</a> , (2009).</li><li>Bergeron, M., Lustyik, G., Phaneuf, S., Ding, T., Nicholson, J. K., Janossy, G., Shapiro, H., Barnett, D., Mandy, F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Stability+of+currently+used+cytometers+facilitates+the+identification+of+pipetting+errors+and+their+volumetric+operation:+&#34;time&#34;+can+tell+all.">Stability of currently used cytometers facilitates the identification of pipetting errors and their volumetric operation: &#34;time&#34; can tell all.</a> Cytometry B Clin Cytom. 52, 37-39 (2003).</li><li>Coulter, B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=.">.</a> Flow Cytometer Alignment Verification Package insert of Flow-CheckTM Fluorospheres. Volume PN 4276179-LA. , (2008).</li><li>Coulter, B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=.">.</a> Flow-SetTM Fluorospheres (Flow Cytometer Standardization Fluorospheres). Package insert of Flow-SetTM Fluorospheres. Volume PN 6607007. , (2007).</li><li>Coulter, B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=.">.</a> Immuno-TrolTM Cells. Package insert of Immuno-TrolTM Cells. Volume PN 6607077. , (2007).</li><li>. Beckman Coulter Hematology IQAP program Available from: <a target="_blank" href="https://www.beckmancoulter.com/wsrportal/wsr/support/quality-assurance-programs/interlaboratory-quality-assurance-program-iqap/index.htm">https://www.beckmancoulter.com/wsrportal/wsr/support/quality-assurance-programs/interlaboratory-quality-assurance-program-iqap/index.htm</a> (2009)</li><li>Glencross, D. K., Aggett, H. M., Stevens, W. S., Mandy, F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=African+regional+external+quality+assessment+for+CD4+T-cell+enumeration:+development,+outcomes,+and+performance+of+laboratories.">African regional external quality assessment for CD4 T-cell enumeration: development, outcomes, and performance of laboratories.</a> Cytometry B Clin Cytom. 74, S69-S79 (2008).</li><li>Tilling, R., Kinloch, S., Goh, L. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Parallel+decline+of+CD8+/CD38+++T+cells+and+viraemia+in+response+to+quadruple+highly+active+antiretroviral+therapy+in+primary+HIV+infection.">Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.</a> AIDS. 16, 589-596 (2002).</li><li>Coulter, B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=.">.</a> FLOWCARETM PLG CD4 Reagent (CD45-FITC/CD4-PE). Package insert of FLOWCARETM PLG CD4 Reagent. , (2004).</li><li>Coulter, B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=.">.</a> Flow-CountTM Fluorospheres. PN 7507992-M. , (2007).</li><li>Scott, L. E., Glencross, D. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Monitoring+reproducibility+of+single+analysis,+single+platform+CD4+cell+counts+in+a+high+volume,+low+resource+laboratory+setting+using+sequential+bead+count+rates.">Monitoring reproducibility of single analysis, single platform CD4 cell counts in a high volume, low resource laboratory setting using sequential bead count rates.</a> Cytometry B Clin Cytom. 67, 31-32 (2005).</li><li>Storie, I., Sawle, A., Goodfellow, K., Whitby, L., Granger, V., Reilly, J. T., Barnett, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Flow+rate+calibration:+a+new+approach+for+performing+absolute+cell+counts.">Flow rate calibration: a new approach for performing absolute cell counts.</a> Cytometry B Clin Cytom. 55, 1-7 (2003).</li><li>Coetzee, L., Lawrie, D., Stevens, W., Glencross, D. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Evaluation+of+pipetting+methodology+to+assess+precision+and+accuracy+of+single+platform+PLG/CD4+enumeration.">Evaluation of pipetting methodology to assess precision and accuracy of single platform PLG/CD4 enumeration.</a> , (2006).</li><li>Borowitz, M. J., Guenther, K. L., Shults, K. E., Stelzer, G. T. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Immunophenotyping+of+acute+leukemia+by+flow+cytometric+analysis.+Use+of+CD45+and+right-angle+light+scatter+to+gate+on+leukemic+blasts+in+three-color+analysis.">Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis.</a> Am J Clin Pathol. 100, 534-540 (1993).</li><li>Mokone, G. N., Lawrie, D., Coetzee, L., Glencross, D. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Interpretation+of+CD45+patterns+in+the+PanLeucoGating+CD4+test+can+be+used+for+diagnosis+of+white+cell+abnormalities.">Interpretation of CD45 patterns in the PanLeucoGating CD4 test can be used for diagnosis of white cell abnormalities.</a> Poster presentation. , (2007).</li><li>Lawrie, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+wide-spread+clinical+uses+of+PanLeucoGating+technology+in+the+HIV+diagnosis+oriented+immunohaematology+laboratory.">The wide-spread clinical uses of PanLeucoGating technology in the HIV diagnosis oriented immunohaematology laboratory.</a> PhD Thesis, in preparation. , (2010).</li><li>Badri, M., Lawn, S. D., Wood, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Utility+of+CD4+cell+counts+for+early+prediction+of+virological+failure+during+antiretroviral+therapy+in+a+resource-limited+setting.">Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting.</a> BMC Infect Dis. 8, 89 (2008).</li><li>Peter, T., Badrichani, A., Wu, E., Freeman, R., Ncube, B., Ariki, F., Daily, J., Shimada, Y., Murtagh, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Challenges+in+implementing+CD4+testing+in+resource-limited+settings.">Challenges in implementing CD4 testing in resource-limited settings.</a> Cytometry B Clin Cytom. 74, S123-S130 (2008).</li><li>Denny, T. N., Gelman, R., Bergeron, M., Landay, A., Lam, L., Louzao, R., Mandy, F. F., Schmitz, J., Spira, T., Wilkening, C., Glencross, D. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+North+American+multilaboratory+study+of+CD4+counts+using+flow+cytometric+panLeukogating+(PLG):+a+NIAID-DAIDS+Immunology+Quality+Assessment+Program+Study.">A North American multilaboratory study of CD4 counts using flow cytometric panLeukogating (PLG): a NIAID-DAIDS Immunology Quality Assessment Program Study.</a> Cytometry B Clin Cytom. 74, S52-S64 (2008).</li><li>Janossy, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+changing+pattern+of+&#34;smart&#34;+flow+cytometry+(S-FC)+to+assist+the+cost-effective+diagnosis+of+HIV,+tuberculosis,+and+leukemias+in+resource-restricted+conditions.">The changing pattern of &#34;smart&#34; flow cytometry (S-FC) to assist the cost-effective diagnosis of HIV, tuberculosis, and leukemias in resource-restricted conditions.</a> Biotechnol J. 3, 32-42 (2008).</li></ol>

I diritti di brevetto internazionale per il metodo di CD4 qui descritte sono detenute dalla NHL Sud Africa e attualmente in licenza a BCI, Miami, Fl, USA.

Negli ultimi anni i programmi di carità-driven e sovvenzioni assegnate hanno contribuito alla creazione di alcune pratiche eccellenti in aree cliniche delle risorse limitate del globo con alto carico HIV. I programmi di ART hanno avuto successo nel ridurre la mortalità e sono ora in fase di avvio a più alto CD4 2,3. Ci sono già indicazioni che queste nuove misure si riduce la diffusione dell&#39;infezione da HIV 4,5, nonostante la mancanza di un vaccino contro l&#39;HIV-specifica. Nel nostro video abbiamo documento che, quando il monitoraggio di pazienti in ART, queste tecniche possono essere più mirata e sempre più conveniente rispetto a quella osservata nella pratica di routine nella zona occidentale di laboratori (Lista 1). Tale guida africana approccio potrebbe essere essenziale per sostenere il potenziamento dei servizi di laboratorio in un momento in cui l&#39;infezione da HIV, trattati con ART, sta diventando una malattia cronica. Tale monitoraggio di ART richiede preciso conteggio CD4 e viral-load della relativa tecnologia, un compito più impegnativo per eseguire semplicemente una conta CD4 per l&#39;immissione dei pazienti in gruppi arbitrari per assistere una decisione di iniziare ART 16. Con l&#39;aiuto di questi diagnostica, cioè utilizzando il CD8/CD38 test, è possibile ridurre la VL-relativi costi di monitoraggio in&gt; 60% dei pazienti trattati con ART 16,19. E &#39;anche importante sottolineare che si tratta della CD8/CD38 test 16,17, e non il conteggio dei CD4 37, che rischia di raccogliere i primi segni di rimbalzi VL e / o la mancanza di compliance del paziente a prendere il farmaco. Un elemento essenziale di un coordinamento efficiente servizio centrale è la disponibilità di una grande rete nazionale o regionale, supportata da esperti e consulenti accademici che hanno familiarità con gli aspetti tecnici e medici del funzionamento. Questo è dimostrato dalle attività della rete del Sud Africa e la NHL CD4-PLG.net programmi di formazione 33, 36 che di incoraggiamento, l&#39;istruzione e la valutazione della qualità per i centri più piccoli e queste possono anche includere &#39;point-of-care&#39; servizi. È importante sottolineare che le operazioni di laboratori centrali e point-of-care sono complementari. Mentre il primo ha il doppio ruolo di providing una soluzione economica su larga scala il funzionamento del servizio così come formazione di base / avanzato per la periferica laboratori 33,38, il secondo contribuisce a controllare la diffusione dell&#39;arte attraverso l&#39;assunzione di pazienti HIV + che sono eleggibili per ARTE da una base più ampia, comprese le cliniche rurali. Qui una certa cautela è necessaria perché il punto-of-care diagnostica può essere molto più costoso e non garantisce automaticamente la precisione 38. E &#39;pertanto opportuno mantenere il sistema a due livelli e per facilitare il coordinamento tra i due livelli, senza consentire sia il braccio a diminuire. In conclusione, nel campo del monitoraggio diagnostico della gestione clinica delle malattie infettive una necessaria riduzione dei costi può essere raggiunta dai servizi che utilizzano apt meno costoso e meglio coordinata la tecnologia moderna con una qualità notevolmente migliorata 13,39. Ben organizzata nazionali (e regionali) le disposizioni di servizio diagnostico dovrebbe essere meglio supportato 6-8, evitando uno scenario in cui praticamente tutte le sovvenzioni è sprecato sui metodi costosi e / o imputati, non appena questi vengono importati da paesi ricchi senza un accurato pre- preventiva controllo costruttivo. Allo stesso modo, un design più flessibile di studi clinici terapeutici con il pieno coinvolgimento dei medici locali e il personale sanitario dovrebbe portare alla riduzione dei inutilmente frequenti e / o troppo ambiziosi test di laboratorio 3. Questa politica avrebbe dato più possibilità di una più piena utilizzazione dei risultati accurati disponibili diagnostici in una valutazione coordinata clinica / laboratorio dei pazienti trattati con ART. Queste diagnostica intelligente potrebbe anche essere introdotto per l&#39;paesi poveri di risorse 8 nel campo della tubercolosi e leucemie utilizzando una piattaforma esistente citometria a flusso familiare 40.

comprehensive &amp; cost effective laboratory monitoring of hiv/aids: an african role model

Vi presentiamo il video di assistere la terapia antiretrovirale (ART) da un servizio di laboratorio apt - rappresenta un sud-africano modello economico per analisi su larga scala diagnostica. In paesi a basso reddito ART poco costoso sono trasformato le prospettive per la sopravvivenza dei pazienti HIV sieropositivi ma non ci sono dubbi sul fatto che vi sia una necessità per il monitoraggio di laboratorio di Arte e quale costo - in situazioni in cui la qualità complessiva dei servizi patologia può ancora essere molto basso. La risposta appropriata è quella di istituire servizi economicamente sana, con un migliore coordinamento e più rigorosa valutazione della qualità interna di quella osservata nei paesi occidentali. Questo video, fotografato nel luogo nei Servizi Laboratorio Nazionale di Salute (NHL-SA) presso l&#39;Università di Witwatersrand, Johannesburg, Sud Africa, fornisce un tale sistema coordinato ampliando l&#39;originale a 2 colori CD4-CD45 strategia PanLeucoGating (PLG). Così i sei moduli di presentazione video rivelano la semplicità di un 4-colori saggio di citometria di flusso di combinare le prove ematologiche, immunologiche e virologia legati in un unico tubo. Questi moduli video sono: (i) la messa a punto di strumenti, (ii) le preparazioni del campione, (iii) verifica i conteggi assoluti e di monitoraggio della qualità di ciascun campione da tallone-count-rate, (iv) la heamatological CD45 test per globuli bianchi conta e differenziali, (v) il numero di CD4, e (vi) l&#39;attivazione di cellule T CD8 + CD38 misurata da visualizzare, un parametro di carica virale correlati. Il potenziale di risparmi sono notevoli. Questo accordo è un primo esempio per la possibilità di effettuare&gt; 800-1000 test al giorno con un controllo di qualità più severe di quella applicata nei laboratori occidentali, e anche con un trasferimento di tecnologia ad altri laboratori all&#39;interno di una NHL-SA rete. Consulenti esperti, responsabili di laboratorio e responsabili delle politiche che portano il dovere di prendere decisioni circa l&#39;introduzione di moderne tecnologie mediche spesso non sono in grado di vedere gli ultimi dettagli tecnici, effettuato nei laboratori regionale di grandi dimensioni con carichi enormi di carico di lavoro. Quindi questo video mostra i dettagli di questi nuovi sviluppi.

Watch this Scientific Journal Video about Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model at JoVE.com

Comprehensive &amp; Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Terapia antiretrovirale per il trattamento di HIV / AIDS è monitorato in Sud Africa su larga scala. Citometria a flusso è combinato per ematologia (CD45), immunologia (CD4) e virali a carico collegato CD38 test. Registrato al NHL-SA laboratori, Johannesburg, questi metodi moderni sono costo-efficaci con accresciuto controllo locale di qualità interno, che servono come modelli per le risorse limitate diagnostica.

Completa dei costi e monitoraggio di laboratorio efficace di HIV / AIDS: un modello di ruolo africano

We present the video about assisting anti-retroviral therapy (ART) by an apt laboratory service - representing a South-African role model for economical ...

comprehensive-cost-effective-laboratory-monitoring-hivaids-an-african

Research

JoVE Journal

Immunology and Infection

16.6K Views.  National Health Laboratory Services (NHLS-SA). Terapia antiretrovirale per il trattamento di HIV / AIDS è monitorato in Sud Africa su larga scala. Citometria a flusso è combinato per ematologia (CD45), immunologia (CD4) e virali a carico collegato CD38 test. Registrato al NHL-SA laboratori, Johannesburg, questi metodi moderni sono costo-efficaci con accresciuto controllo locale di qualità interno, che servono come modelli per le risorse limitate diagnostica.

Video: Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Background: Ovarian cancer is generally diagnosed at an advanced stage where the case/fatality ratio is high and thus remains the most lethal of all gynecologic malignancies among US women 1,2,3. Serous tumors are the most widespread forms of ovarian cancer and 4,5 the Tg-MISIIR-TAg transgenic represents the only mouse model that spontaneously develops this type of tumors. Tg-MISIIR-TAg mice express SV40 transforming region under control of the Mullerian Inhibitory Substance type II Receptor (MISIIR) gene promoter 6. Additional transgenic lines have been identified that express the SV40 TAg transgene, but do not develop ovarian tumors. Non-tumor prone mice exhibit typical lifespan for C57Bl/6 mice and are fertile. These mice can be used as syngeneic allograft recipients for tumor cells isolated from Tg-MISIIR-TAg-DR26 mice.
Objective: Although tumor imaging is possible 7, early detection of deep tumors is challenging in small living animals. To enable preclinical studies in an immunologically intact animal model for serous ovarian cancer, we describe a syngeneic mouse model for this type of ovarian cancer that permits in vivo imaging, studies of the tumor microenvironment and tumor immune responses.
Methods: We first derived a TAg+ mouse cancer cell line (MOV1) from a spontaneous ovarian tumor harvested in a 26 week-old DR26 Tg-MISIIR-TAg female. Then, we stably transduced MOV1 cells with TurboFP635 Lentivirus mammalian vector that encodes Katushka, a far-red mutant of the red fluorescent protein from sea anemone Entacmaea quadricolor with excitation/emission maxima at 588/635 nm 8,9,10. We orthotopically implanted MOV1Kat in the ovary 11,12,13,14 of non-tumor prone Tg-MISIIR-TAg female mice. Tumor progression was followed by in vivo optical imaging and tumor microenvironment was analyzed by immunohistochemistry.
Results: Orthotopically implanted MOV1Kat cells developed serous ovarian tumors. MOV1Kat tumors could be visualized by in vivo imaging up to three weeks after implantation (fig. 1) and were infiltrated with leukocytes, as observed in human ovarian cancers 15 (fig. 2).
Conclusions: We describe an orthotopic model of ovarian cancer suitable for in vivo imaging of early tumors due to the high pH-stability and photostability of Katushka in deep tissues. We propose the use of this novel syngeneic model of serous ovarian cancer for in vivo imaging studies and monitoring of tumor immune responses and immunotherapies.

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

To study in vivo tumor growth and tumor microenvironment, we used a syngeneic and orthotopic mouse model of ovarian cancer in immunocompetent animals. We transduced a mouse tumor cell line (MOV1) with Katushka fluorescent protein (MOV1KAT) and here we show its orthotopic implantation in ovary and in vivo imaging.

Un modello ortotopico di carcinoma ovarico sieroso in topi immunocompetenti per In vivo Tumore Imaging e monitoraggio del tumore Risposte immunitarie

Background: Ovarian cancer is generally diagnosed at an advanced stage where the case/fatality ratio is high and thus remains the most lethal of all ...

Ricerca

Immunologia e infezioni

An Analytical Tool-box for Comprehensive Biochemical, Structural and Transcriptome Evaluation of Oral Biofilms Mediated by Mutans Streptococci

Biofilms are highly dynamic, organized and structured communities of microbial cells enmeshed in an extracellular matrix of variable density and composition 1, 2. In general, biofilms develop from initial microbial attachment on a surface followed by formation of cell clusters (or microcolonies) and further development and stabilization of the microcolonies, which occur in a complex extracellular matrix. The majority of biofilm matrices harbor exopolysaccharides (EPS), and dental biofilms are no exception; especially those associated with caries disease, which are mostly mediated by mutans streptococci 3. The EPS are synthesized by microorganisms (S. mutans, a key contributor) by means of extracellular enzymes, such as glucosyltransferases using sucrose primarily as substrate 3.
Studies of biofilms formed on tooth surfaces are particularly challenging owing to their constant exposure to environmental challenges associated with complex diet-host-microbial interactions occurring in the oral cavity. Better understanding of the dynamic changes of the structural organization and composition of the matrix, physiology and transcriptome/proteome profile of biofilm-cells in response to these complex interactions would further advance the current knowledge of how oral biofilms modulate pathogenicity. Therefore, we have developed an analytical tool-box to facilitate biofilm analysis at structural, biochemical and molecular levels by combining commonly available and novel techniques with custom-made software for data analysis. Standard analytical (colorimetric assays, RT-qPCR and microarrays) and novel fluorescence techniques (for simultaneous labeling of bacteria and EPS) were integrated with specific software for data analysis to address the complex nature of oral biofilm research.
The tool-box is comprised of 4 distinct but interconnected steps (Figure 1): 1) Bioassays, 2) Raw Data Input, 3) Data Processing, and 4) Data Analysis. We used our in vitro biofilm model and specific experimental conditions to demonstrate the usefulness and flexibility of the tool-box. The biofilm model is simple, reproducible and multiple replicates of a single experiment can be done simultaneously 4, 5. Moreover, it allows temporal evaluation, inclusion of various microbial species 5 and assessment of the effects of distinct experimental conditions (e.g. treatments 6; comparison of knockout mutants vs. parental strain 5; carbohydrates availability 7). Here, we describe two specific components of the tool-box, including (i) new software for microarray data mining/organization (MDV) and fluorescence imaging analysis (DUOSTAT), and (ii) in situ EPS-labeling. We also provide an experimental case showing how the tool-box can assist with biofilms analysis, data organization, integration and interpretation.

Biofilms formed on tooth surfaces are highly complex and exposed to constant innate and exogenous environmental challenges, which modulate their architecture, physiology and transcriptome. We developed a toolbox to examine the composition, structural organization and gene expression of oral biofilms, which can be adapted to other areas of biofilm research.

Una analitica Tool-box per la valutazione completa biochimici, strutturali e trascrittoma di biofilm orale mediata da Mutans Streptococchi

Biofilms are highly dynamic, organized and structured communities of microbial cells enmeshed in an extracellular matrix of variable density and ...

Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3

Background: Prior to receiving a drug from CCR5-antagonist class in HIV therapy, a patient must undergo an HIV tropism test to confirm that his or her viral population uses the CCR5 coreceptor for cellular entry, and not an alternative coreceptor. One approach to tropism testing is to examine the sequence of the V3 region of the HIV envelope, which interacts with the coreceptor.
Methods: Viral RNA is extracted from blood plasma. The V3 region is amplified in triplicate with nested reverse transcriptase-PCR. The amplifications are then sequenced and analyzed using the software, RE_Call. Sequences are then submitted to a bioinformatic algorithm such as geno2pheno to infer viral tropism from the V3 region. Sequences are inferred to be non-R5 if their geno2pheno false positive rate falls below 5.75%. If any one of the three sequences from a sample is inferred to be non-R5, the patient is unlikely to respond to a CCR5-antagonist.

HIV tropism can be inferred from the V3 region of the viral envelope. V3 is PCR amplified in triplicate using nested RT-PCR, sequenced, and interpreted using bioinformatic software. Samples with with 1 or more sequence(s) with low g2P scores are classified as non-R5 virus.

Inferenza genotipica del virus HIV-1 Tropismo utilizzo basati sulla popolazione sequenziamento del V3

Background: Prior to receiving a drug from CCR5-antagonist class in HIV therapy, a patient must undergo an HIV tropism test to confirm that his or her ...

Cost-effective Method for Microbial Source Tracking Using Specific Human and Animal Viruses

Microbial contamination of the environment represents a significant health risk. Classical bacterial fecal indicators have shown to have significant limitations, viruses are more resistant to many inactivation processes and standard fecal indicators do not inform on the source of contamination. The development of cost-effective methods for the concentration of viruses from water and molecular assays facilitates the applicability of viruses as indicators of fecal contamination and as microbial source tracking (MST) tools. Adenoviruses and polyomaviruses are DNA viruses infecting specific vertebrate species including humans and are persistently excreted in feces and/or urine in all geographical areas studied. In previous studies, we suggested the quantification of human adenoviruses (HAdV) and JC polyomaviruses (JCPyV) by quantitative PCR (qPCR) as an index of human fecal contamination. Recently, we have developed qPCR assays for the specific quantification of porcine adenoviruses (PAdV) and bovine polyomaviruses (BPyV) as animal fecal markers of contamination with sensitivities of 1-10 genome copies per test tube. In this study, we present the procedure to be followed to identify the source of contamination in water samples using these tools. As example of representative results, analysis of viruses in ground water presenting high levels of nitrates is shown.
Detection of viruses in low or moderately polluted waters requires the concentration of the viruses from at least several liters of water into a much smaller volume, a procedure that usually includes two concentration steps in series. This somewhat cumbersome procedure and the variability observed in viral recoveries significantly hamper the simultaneous processing of a large number of water samples.
In order to eliminate the bottleneck caused by the two-step procedures we have applied a one-step protocol developed in previous studies and applicable to a diversity of water matrices. The procedure includes: acidification of ten-liter water samples, flocculation by skimmed milk, gravity sedimentation of the flocculated materials, collection of the precipitate and centrifugation, resuspension of the precipitate in 10 ml phosphate buffer. The viral concentrate is used for the extraction of viral nucleic acids and the specific adenoviruses and polyomaviruses of interest are quantified by qPCR. High number of samples may be simultaneously analyzed using this low-cost concentration method.
The procedure has been applied to the analysis of bathing waters, seawater and river water and in this study, we present results analyzing groundwater samples. This high-throughput quantitative method is reliable, straightforward, and cost-effective.

The study describes a cost-effective method for the identification of the source of fecal/urine contamination or contamination by nitrates in water using qPCR for the specific quantification of human/porcine/bovine DNA viruses, adenoviruses and polyomaviruses, proposed as MST tools.

Costo-efficace metodo per il rilevamento di origine microbica Utilizzando specifici virus umani e animali

Microbial contamination of the environment represents a significant health risk. Classical bacterial fecal indicators have shown to have significant ...

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model

Graft-versus-host disease (GVHD) is the limiting barrier to the broad use of bone marrow transplant as a curative therapy for a variety of hematological deficiencies. GVHD is caused by mature alloreactive T cells present in the bone marrow graft that are infused into the recipient and cause damage to host organs. However, in mice, T cells must be added to the bone marrow inoculum to cause GVHD. Although extensive work has been done to characterize T cell responses post transplant, bioluminescent imaging technology is a non-invasive method to monitor T cell trafficking patterns in vivo. 
Following lethal irradiation, recipient mice are transplanted with bone marrow cells and splenocytes from donor mice. T cell subsets from L2G85.B6 (transgenic mice that constitutively express luciferase) are included in the transplant. By only transplanting certain T cell subsets, one is able to track specific T cell subsets in vivo, and based on their location, develop hypotheses regarding the role of specific T cell subsets in promoting GVHD at various time points. At predetermined intervals post transplant, recipient mice are imaged using a Xenogen IVIS CCD camera. Light intensity can be quantified using Living Image software to generate a pseudo-color image based on photon intensity (red = high intensity, violet = low intensity). 
Between 4-7 days post transplant, recipient mice begin to show clinical signs of GVHD. Cooke et al.1 developed a scoring system to quantitate disease progression based on the recipient mice fur texture, skin integrity, activity, weight loss, and posture. Mice are scored daily, and euthanized when they become moribund. Recipient mice generally become moribund 20-30 days post transplant. 
Murine models are valuable tools for studying the immunology of GVHD. Selectively transplanting particular T cell subsets allows for careful identification of the roles each subset plays. Non-invasively tracking T cell responses in vivo adds another layer of value to murine GVHD models.

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model

Murine bone marrow transplantation is a widely used technique to study immunological mechanisms governing graft-versus-host disease in humans. The ability to monitor T cell trafficking patterns in vivo allows for detailed analysis of the development and perpetuation of T cell responses during graft-versus-host disease.

Induzione di Graft-versus-host disease e<em&gt; In Vivo</em&gt; T monitoraggio cellulare Utilizzando un MHC-abbinato modello murino

Graft-versus-host disease (GVHD) is the limiting barrier to the broad use of bone marrow transplant as a curative therapy for a variety of hematological ...

Using Fluorescent Proteins to Monitor Glycosome Dynamics in the African Trypanosome

Trypanosoma brucei is a kinetoplastid parasite that causes human African trypanosomiasis (HAT), or sleeping sickness, and a wasting disease, nagana, in cattle1. The parasite alternates between the bloodstream of the mammalian host and the tsetse fly vector. The composition of many cellular organelles changes in response to these different extracellular conditions2-5.
Glycosomes are highly specialized peroxisomes in which many of the enzymes involved in glycolysis are compartmentalized. Glycosome composition changes in a developmental and environmentally regulated manner4-11. Currently, the most common techniques used to study glycosome dynamics are electron and fluorescence microscopy; techniques that are expensive, time and labor intensive, and not easily adapted to high throughput analyses.
To overcome these limitations, a fluorescent-glycosome reporter system in which enhanced yellow fluorescent protein (eYFP) is fused to a peroxisome targeting sequence (PTS2), which directs the fusion protein to glycosomes12, has been established. Upon import of the PTS2eYFP fusion protein, glycosomes become fluorescent. Organelle degradation and recycling results in the loss of fluorescence that can be measured by flow cytometry. Large numbers of cells (5,000 cells/sec) can be analyzed in real-time without extensive sample preparation such as fixation and mounting. This method offers a rapid way of detecting changes in organelle composition in response to fluctuating environmental conditions.

Glycosome dynamics in African trypanosomes are difficult to study by traditional cell biology techniques such as electron and fluorescence microscopy. As a means of observing dynamic organelle behavior, a fluorescent-organelle reporter system has been used in conjunction with flow cytometry to monitor real-time glycosome dynamics in live parasites.

Utilizzo di proteine ​​fluorescenti per monitorare Glycosome Dynamics in Tripanosoma africano

Trypanosoma brucei is a kinetoplastid parasite that causes human African trypanosomiasis (HAT), or sleeping sickness, and a wasting disease, nagana, in ...

Safety Precautions and Operating Procedures in an (A)BSL-4 Laboratory: 1. Biosafety Level 4 Suit Laboratory Suite Entry and Exit Procedures

Biosafety level 4 (BSL-4) suit laboratories are specifically designed to study high-consequence pathogens for which neither infection prophylaxes nor treatment options exist. The hallmarks of these laboratories are: custom-designed airtight doors, dedicated supply and exhaust airflow systems, a negative-pressure environment, and mandatory use of positive-pressure (&#8220;space&#8221;) suits. The risk for laboratory specialists working with highly pathogenic agents is minimized through rigorous training and adherence to stringent safety protocols and standard operating procedures. Researchers perform the majority of their work in BSL-2 laboratories and switch to BSL-4 suit laboratories when work with a high-consequence pathogen is required. Collaborators and scientists considering BSL-4 projects should be aware of the challenges associated with BSL-4 research both in terms of experimental technical limitations in BSL-4 laboratory space and the increased duration of such experiments. Tasks such as entering and exiting the BSL-4 suit laboratories are considerably more complex and time-consuming compared to BSL-2 and BSL-3 laboratories. The focus of this particular article is to address basic biosafety concerns and describe the entrance and exit procedures for the BSL-4 laboratory at the NIH/NIAID Integrated Research Facility at Fort Detrick. Such procedures include checking external systems that support the BSL-4 laboratory, and inspecting and donning positive-pressure suits, entering the laboratory, moving through air pressure-resistant doors, and connecting to air-supply hoses. We will also discuss moving within and exiting the BSL-4 suit laboratories, including using the chemical shower and removing and storing positive-pressure suits.

Safety Precautions and Operating Procedures in an ABSL-4 Laboratory: 1. Biosafety Level 4 Suit Laboratory Suite Entry and Exit Procedures

Although researchers are generally knowledgeable about procedures and safety precautions required for biosafety level 1 or 2 (BSL-1/2) experiments, they may not be familiar with experimental procedures in BSL-4 suit laboratories. This article provides a detailed visual demonstration of BSL-4 suit laboratory systems check, laboratory entry, movement, and exit procedures.

Misure di sicurezza e procedure operative in un (A) BSL-4 di laboratorio: 1. livello di biosicurezza 4 Suit Laboratorio Suite entrata e di uscita Procedure

Biosafety level 4 (BSL-4) suit laboratories are specifically designed to study high-consequence pathogens for which neither infection prophylaxes nor ...

Safety Precautions and Operating Procedures in an (A)BSL-4 Laboratory: 3. Aerobiology

Aerosol or inhalational studies of high-consequence pathogens have recently been increasing in number due to the perceived threat of intentional aerosol releases or unexpected natural aerosol transmission. Specific laboratories designed to perform these experiments require tremendous engineering controls to provide a safe and secure working environment and constant systems maintenance to sustain functionality. Class III biosafety cabinets, also referred to as gloveboxes, are gas-tight enclosures with non-opening windows. These cabinets are maintained under negative pressure by double high-efficiency-particulate-air (HEPA)-filtered exhaust systems and are the ideal primary containment for housing aerosolization equipment. A well planned workflow between staff members within high containment from, for instance, an animal biosafety level-4 (ABSL-4) suit laboratory to the ABSL-4 cabinet laboratory is a crucial component for successful experimentation. For smooth study execution, establishing a communication network, moving equipment and subjects, and setting up and placing equipment, requires staff members to meticulously plan procedures prior to study initiation. Here, we provide an overview and a visual representation of how aerobiology research is conducted at the National Institutes of Health, National Institute of Allergy and Infectious Diseases Integrated Research Facility at Fort Detrick, Maryland, USA, within an ABSL-4 environment.

Safety Precautions and Operating Procedures in an ABSL-4 Laboratory: 3. Aerobiology

As high-consequence pathogens can potentially infect subjects through airborne particles, aerobiology has been increasingly applied in pathogenesis research and medical countermeasure development. We present a detailed visual demonstration of aerobiology procedures during an aerosol challenge in nonhuman primates in an animal biosafety level 4 maximum containment environment.

Misure di sicurezza e procedure operative in un (A) BSL-4 di laboratorio: 3. aerobiologia

Aerosol or inhalational studies of high-consequence pathogens have recently been increasing in number due to the perceived threat of intentional aerosol ...

Bioluminescence Imaging to Detect Late Stage Infection of African Trypanosomiasis

Human African trypanosomiasis (HAT) is a multi-stage disease that manifests in two stages; an early blood stage and a late stage when the parasite invades the central nervous system (CNS). In vivo study of the late stage has been limited as traditional methodologies require the removal of the brain to determine the presence of the parasites.
Bioluminescence imaging is a non-invasive, highly sensitive form of optical imaging that enables the visualization of a luciferase-transfected pathogen in real-time. By using a transfected trypanosome strain that has the ability to produce late stage disease in mice we are able to study the kinetics of a CNS infection in a single animal throughout the course of infection, as well as observe the movement and dissemination of a systemic infection.
Here we describe a robust protocol to study CNS infections using a bioluminescence model of African trypanosomiasis, providing real time non-invasive observations which can be further analyzed with optional downstream approaches.

This manuscript describes the use of a bioluminescent strain of African trypanosomes to enable the tracking of late stage infection and demonstrates how in vivo live imaging can be used to visualize infections within the central nervous system in real-time.

Bioluminescenza Imaging per rilevare fase avanzata di infezione di africani Tripanosomiasi

Human African trypanosomiasis (HAT) is a multi-stage disease that manifests in two stages; an early blood stage and a late stage when the parasite invades ...

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Clostridium difficile is an anaerobic, gram-positive, spore-forming enteric pathogen that is associated with increasing morbidity and mortality and consequently poses an urgent threat to public health. Recurrence of a C. difficile infection (CDI) after successful treatment with antibiotics is high, occurring in 20-30% of patients, thus necessitating the discovery of novel therapeutics against this pathogen. Current animal models of CDI result in high mortality rates and thus do not approximate the chronic, insidious disease manifestations seen in humans with CDI. To evaluate therapeutics against C. difficile, a mouse model approximating human disease utilizing a clinically-relevant strain is needed. This protocol outlines the cefoperazone mouse model of CDI using a clinically-relevant and genetically-tractable strain, R20291. Techniques for clinical disease monitoring, C. difficile bacterial enumeration, toxin cytotoxicity, and histopathological changes throughout CDI in a mouse model are detailed in the protocol. Compared to other mouse models of CDI, this model is not uniformly lethal at the dose administered, allowing for the observation of a prolonged clinical course of infection concordant with the human disease. Therefore, this cefoperazone mouse model of CDI proves a valuable experimental platform to assess the effects of novel therapeutics on the amelioration of clinical disease and on the restoration of colonization resistance against C. difficile.

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

This protocol outlines the cefoperazone mouse model of Clostridium difficile infection (CDI) using a clinically-relevant and genetically-tractable strain, R20291. Emphasis on clinical disease monitoring, C. difficile bacterial enumeration, toxin cytotoxicity, and histopathological changes throughout CDI in a mouse model are detailed in the protocol.

Cefoperazone trattati modello murino di clinicamente rilevanti<em&gt; Clostridium difficile</em&gt; R20291 Strain

Clostridium difficile is an anaerobic, gram-positive, spore-forming enteric pathogen that is associated with increasing morbidity and mortality and ...